Lonza Announces Withdrawal of Bid for Patheon
While Lonza continues to believe that entry into the formulation contract manufacturing business fits within Lonza's current growth strategy, a combination of factors including value considerations, the rejection of the Lonza proposal by the majority shareholder of Patheon, and the availability to Lonza of possible alternatives makes the proposed acquisition unattractive to Lonza at this time. Lonza and Patheon have also agreed to terminate discussions regarding other strategic options that would not involve the sale of JLL's shares.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.